LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

LLY

989.23

-1.47%↓

JNJ

227.42

+0.29%↑

ABBV

209.43

-0.47%↓

UNH

387.03

-1.68%↓

AZN

184.21

+1.43%↑

Home・Lista de Ações・Denali Therapeutics Inc

Denali Therapeutics Inc

Abrir

SetorSaúde

18.41 -1.13

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

18.48

Máximo

19.04

Indicadores-chave
By Trading Economics
Rendimento	102K -128M
EPS	-0.69
Funcionários	503
EBITDA	-9.8M -135M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+92.86% upside

Dividendos
By Dow Jones
Próximos Ganhos	7 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	159M 3.1B
Abertura anterior	19.54
Fecho anterior	18.41

Sentimento de Notícias

By Acuity

50%

136 / 345 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

13.355 / 16.44 Suporte e Resistência

Denali Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

17 de mai. de 2026, 23:53 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Buy Majority Stake in India Life Insurer for $389 Million

15 de mai. de 2026, 22:47 UTC

Ações em Alta

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 de mai. de 2026, 22:16 UTC

Aquisições, Fusões, Aquisições de Empresas

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 de mai. de 2026, 22:00 UTC

Grandes Movimentos do Mercado

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 de mai. de 2026, 18:09 UTC

Grandes Movimentos do Mercado

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

17 de mai. de 2026, 23:50 UTC

Conversa de Mercado

Gold Consolidates; May be Weighed by Fed Rate-Hike Expectations -- Market Talk

17 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

17 de mai. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

17 de mai. de 2026, 23:36 UTC

Conversa de Mercado

Oil Rises Amid Prospects of Prolonged Strait of Hormuz Closure -- Market Talk

17 de mai. de 2026, 23:07 UTC

Aquisições, Fusões, Aquisições de Empresas

UOB: Transactions Part of Group's Capital Reallocation Strategy

17 de mai. de 2026, 23:06 UTC

Aquisições, Fusões, Aquisições de Empresas

UOB: Share Sale Agreements Entered With Singland Properties

17 de mai. de 2026, 23:05 UTC

Aquisições, Fusões, Aquisições de Empresas

UOB: Divestments' Aggregate Consideration of S$299M in Cash

17 de mai. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Fund Stake Acquisition via Internal Resources

17 de mai. de 2026, 22:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Acquire Stake for $389 Million

17 de mai. de 2026, 22:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Prudential PLC to Acquire 75% Stake in Bharti Life Insurance

16 de mai. de 2026, 16:27 UTC

Aquisições, Fusões, Aquisições de Empresas

NextEra Is In Talks to Buy Dominion, Report Says. What a Deal Could Mean. -- Barrons.com

16 de mai. de 2026, 15:26 UTC

Aquisições, Fusões, Aquisições de Empresas

NextEra Energy Near Deal for Rival Utility Dominion -- WSJ

16 de mai. de 2026, 08:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 22:17 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:59 UTC

Aquisições, Fusões, Aquisições de Empresas

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 de mai. de 2026, 21:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 de mai. de 2026, 21:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 de mai. de 2026, 21:16 UTC

Conversa de Mercado

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

15 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

15 de mai. de 2026, 20:19 UTC

Ações em Alta

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 de mai. de 2026, 19:41 UTC

Aquisições, Fusões, Aquisições de Empresas

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 de mai. de 2026, 19:35 UTC

Conversa de Mercado

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 de mai. de 2026, 19:33 UTC

Conversa de Mercado

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 de mai. de 2026, 18:35 UTC

Ganhos

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

Comparação entre Pares

Variação de preço

Denali Therapeutics Inc Previsão

Preço-alvo

By TipRanks

92.86% parte superior

Previsão para 12 meses

Média 35.91 USD 92.86%

Máximo 42 USD

Mínimo 23 USD

Com base em 14 analistas de Wall Street que oferecem metas de preço de 12 meses para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

14 ratings

Comprar

Manter

Vender

Com base em 14 analistas que deram avaliações de ações para Denali Therapeutics Inc - Dist nos últimos 3 meses.

Pontuação Técnica

By Trading Central

13.355 / 16.44Suporte e Resistência

Recent bearish events outweigh bullish events.

The bullish and bearish events are balanced.

All events are bearish.

Sentimento

By Acuity

136 / 345 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.